Nine-year follow-up of interleukin 6 in chronic obstructive pulmonary disease – complementary results from previous studies

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorPrudente, Robson-
Autor(es): dc.creatorFerrari, Renata-
Autor(es): dc.creatorMesquita, Carolina-
Autor(es): dc.creatorMachado, Luiz-
Autor(es): dc.creatorFranco, Estefânia-
Autor(es): dc.creatorGodoy, Irma-
Autor(es): dc.creatorTanni, Suzana-
Data de aceite: dc.date.accessioned2025-08-21T17:46:47Z-
Data de disponibilização: dc.date.available2025-08-21T17:46:47Z-
Data de envio: dc.date.issued2022-04-29-
Data de envio: dc.date.issued2022-04-29-
Data de envio: dc.date.issued2020-12-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.2147/COPD.S328266-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/229865-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/229865-
Descrição: dc.descriptionBackground: Systemic manifestations of chronic obstructive pulmonary disease (COPD) are related to increased systemic inflammatory process; however, it is not entirely clear how much they are related and how the systemic inflammation, in particular interleukin-6 (IL-6), is associated with exacerbation and mortality risk. Objective: To evaluate the role of IL-6 in COPD patients over nine years. Study Design and Methods: A total of 133 COPD patients were assessed at baseline between 2004 and 2006 and reassessed after three and nine years through clinical evaluation, comorbidities, hematological blood count and IL-6 analysis. Results: After nine years, 19 patients lost the follow-up and were not possible to identify the date of death of four patients; 12 refused to participate and 1 could not be involved due to recurrent exacerbations. Therefore, 33 patients were included in the reassessment after nine years of follow-up and 92 patients were included in the Cox mortality analysis with IL-6 as a time-dependent covariate. Regarding the inflammatory profile, in patients who survived after nine years, there was a significant increase in IL-6 [0.4 (0.2–0.8) vs 5.7 (3.4–11) pg/mL; p < 0.001] and reduction in lymphocyte count [2.1 (1.6–2.4) vs 1.4 (1.2–2.1)10^9/L; p < 0.01] with an increase in the neutrophil/lymphocyte ratio (2.0 ± 0.7 vs 2.7 ± 1.2; p = 0.003). The Cox mortality model did not show a statistical significance influence of IL-6 assessed during the follow-up. Conclusion: There was a progressive increase in IL-6 during the follow-up, however, without influence on mortality.-
Descrição: dc.descriptionClinical Hospital of Botucatu Medical School Department of Internal MedicinePneumology Area Botucatu School of Medicine São Paulo State University (UNESP)-
Descrição: dc.descriptionDepartment of Internal Medicine Pneumology Area Botucatu School of Medicine São Paulo State University (UNESP)-
Descrição: dc.descriptionClinical Hospital of Botucatu Medical School Department of Internal MedicinePneumology Area Botucatu School of Medicine São Paulo State University (UNESP)-
Descrição: dc.descriptionDepartment of Internal Medicine Pneumology Area Botucatu School of Medicine São Paulo State University (UNESP)-
Formato: dc.format3019-3026-
Idioma: dc.languageen-
Relação: dc.relationInternational Journal of COPD-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectChronic obstructive pulmonary disease-
Palavras-chave: dc.subjectInflammation-
Palavras-chave: dc.subjectInterleukin-6-
Palavras-chave: dc.subjectMortality-
Palavras-chave: dc.subjectSeverity of illness index-
Título: dc.titleNine-year follow-up of interleukin 6 in chronic obstructive pulmonary disease – complementary results from previous studies-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.